“Pfizer did a lot of good [for] humanity and we are very, very proud of it,” Bourla stated in an interview with CNN Business. “Not only were we able to save so many lives … but we are enjoying high levels of corporate reputation right now. People like us.”
Hoping to get Covid tablet authorized in early 2022
Bourla stated he understands the frustration of fogeys who’re totally vaccinated however can not get their youngest children protected.
“We’re working very intensively on that to make sure we can bring a solution for that,” Bourla stated.
“We are looking at different doses, well below the doses that have been used [for adults and older kids.] We know that it will be safe. What we are looking to see is if that will protect them by giving the lower dose,” he added.
But Bourla pressured to CNN Business that the tablet shouldn’t be meant to be an alternative choice to the vaccine.
Ready to launch an Omicron-specific vaccine if wanted
He conceded, nevertheless, that it’s attainable Pfizer might want to launch a brand new vaccine to particularly goal Omicron or some other future variants. Bourla stated Pfizer is already creating a shot aimed toward Omicron, and that he believes it could possibly be examined and submitted to regulators for approval by March.
If Pfizer wants to provide Omicron-specific pictures, that won’t sluggish the manufacturing of the prevailing vaccine, Bourla stated.
“We are aiming for a four billion [dose] annual manufacturing capacity of our current vaccine. And if we have to switch between the two, the old and the new, we still will make four billion. We don’t expect that we will lose any volume,” he stated.
Bourla additionally acknowledged that there are cynics who query whether or not Pfizer is simply attempting to make as a lot cash as attainable from the vaccine.
After all, Pfizer stated in its newest earnings launch in November that it generated $13 billion in income from the vaccine within the third quarter and that it now expects $36 billion in income from it for the total 12 months.
Bourla advised CNN Business that it’s charging poorer, creating nations much less for the vaccine than it does to wealthier international locations. But price is not the one problem. He stated some international locations, resembling these in distant components of Africa, are “lacking basic infrastructure.”
“They don’t have centers to vaccinate people, particularly in remote places. They do not have enough nurses,” he stated. “Sometimes they are lacking syringes, sometimes they are lacking refrigerators so that they can store the vaccine. So this is unfortunately the situation.”
Bourla is hopeful the World Health Organization and the public-private vaccine alliance Gavi will be capable of assist resolve a few of these points. He additionally stated the corporate is trying into drone supply extra to make sure that folks get the vaccine extra rapidly.
“We are doing everything we can to find ourselves on the right [side] of history,” he stated.
Bourla additionally continued to emphasize that the vaccine is secure and that the one method for all times to return to regular is for folks to get the pictures.
“I don’t see any reason why next year will not be a normal year if we do the simple things that are available for us,” Bourla stated. “If we have very big numbers of people that don’t want to do a third dose or don’t want to vaccinate at all, that’s a problem.”
More to Pfizer than the Covid vaccine
Pfizer and Bourla aren’t resting on their laurels.
The firm has additionally been on the forefront of creating many different promising blockbuster medication resembling blood thinner Eliquis, breast most cancers therapy Ibrance and rheumatoid arthritis tablet Xeljanz, in addition to the Prevnar household of pneumonia vaccines.
Bourla is totally conscious that for a drug firm to stay profitable, it has to have much more promising medication within the pipeline.
Several of Pfizer’s present prime sellers are resulting from lose patent safety within the subsequent few years. Once they expire, that opens the door for cheaper generic medication to compete with them.
“It’s challenging to multitask,” Bourla stated. “But let’s not forget what else we are working on. There are so many medicines for cancer, for other infectious diseases, for cardiovascular diseases, for other diseases.”
“We are heavily invested right now in cancer,” Bourla added. “The biggest percentage of our R&D investment goes into oncology right now.”